home / stock / tlsa / tlsa news

TLSA News and Press, Tiziana Life Sciences plc From 04/11/24

Stock Information
Company Name: Tiziana Life Sciences plc
Stock Symbol: TLSA
Market: NASDAQ
Website: tizianalifesciences.com
Menu
TLSA TLSA Quote TLSA Short TLSA News TLSA Articles TLSA Message Board
Get TLSA Alerts

News, Short Squeeze, Breakout and More Instantly...
TLSA - Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral presentation, titled, &...
TLSA - 3 EV Stocks to Buy on the Dip: March 2024

2024-03-29 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The electric vehicle (EV) market has seen better days. Slower sales growth and price wars have impacted many EV stocks to buy. The Global X Autonomous & Electric Vehicles ETF (NASD...

TLSA - 3 EV Stocks to Buy for the Next Bull Run: March 2024

2024-03-28 06:19:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The electric vehicle (EV) market continues to suffer from an ongoing slump. Slower sales growth and price wars have impacted both large and small EV stocks with investors unsure if it is a...

TLSA - Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease

Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD) Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studies Neuroinflammation modulation m...
TLSA - Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total o...

TLSA - Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical ...

TLSA - Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to comp...
TLSA - Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis

NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Ph...

TLSA - Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davi...

TLSA - Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis

NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company ...
Previous 10 Next 10